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Splicing therapeutics are defined as the deliberate modification of RNA splicing to achieve therapeutic goals.
Various techniques for splicing therapeutics have been described, and most of these involve the use of
antisense oligonucleotide-based compounds that target key elements in the pre-mRNA to control splicing in the
nucleus. In this review, recent developments in splicing therapeutics for the treatment of two specific diseases
are described: correcting the alternative splicing of survival of motor neuron (SMN)2 pre-mRNA to compensate
for the defective SMN1 gene in spinal muscular atrophy, and re-engineering the splicing of apolipoprotein B
pre-mRNA to lower circulating cholesterol levels.
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Introduction
During the process of pre-mRNA splicing the spliceosome, a dynamic complex of five small nuclear
ribonucleoprotein (snRNP) particles and various proteins remove introns from the transcribed pre-mRNA and
join the exons to produce a translatable mRNA [1]. Exon-intron junctions are defined by degenerate cis-
elements: the 5' splice site, the 3' splice site and the branch-point sequence (BPS). The degenerate cis-
elements are necessary but not sufficient for accurate splicing. Other auxiliary sequences and their cognate
factors influence the selection of splice sites. 'Splicing enhancers' are sequences within the pre-mRNA that
promote the use of particular splice sites. Splicing enhancers are present in exons or introns, and are
recognized by activator proteins, such as serine/arginine (SR)-rich proteins [2,3], which promote spliceosomal
assembly on adjacent splice sites [4]. Conversely, 'splicing silencers' are sequences that inhibit the use of
particular splice sites. Elements of the splicing silencer class are recognized by various repressors, such as
polypyrimidine tract binding protein (PTB) [5] and heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) [6].
In the last 15 years, increasing interest has centered on the deliberate modification of RNA splicing for
therapeutic purposes. The impetus for this interest arises from the observation that various mutations that
cause human genetic diseases affect splicing, with approximately 10% of mutations affecting the RNA splice
sites per se [7]. This review describes two therapeutic target pre-mRNAs – survival of motor neuron (SMN)2
and apolipoprotein B (APOB) – to highlight the developments in splicing therapeutics in 2007 and 2008.SMN2: Stimulating inclusion of exon 7
Spinal muscular atrophy (SMA) is a degenerative disease of the motor neurons of the spinal cord anterior horn
and lower brainstem [8]. SMA presents in childhood with muscle weakness and occasionally fatal respiratory
failure, and is caused by mutations of the SMN locus. In humans, the SMN locus is part of an inverted
chromosomal-segment duplication that comprises the SMN1 gene and its paralog SMN2. The SMN protein is
ubiquitously expressed, and the majority (60 to 90%) of the SMN protein is translated from SMN1 mRNA. Point
mutations or deletions in SMN1 have been observed in patients with SMA [9]. The SMN protein is localized in
subnuclear complexes known as Gemini of coiled bodies or 'gems', which are involved in snRNP assembly and
recycling; these gems are absent or greatly reduced in the cells of patients with SMA [10].
There is only a partial deficiency of the SMN protein in SMA, as the mutated SMN1 is partially complemented by
the wild-type copy of SMN2. The copy number of SMN2 is variable because of SMN2 gene duplication or
conversion. The higher the copy numbers of SMN2, the milder the SMA phenotype [11]. The SMN2 gene differs
from SMN1 by five nucleotide changes, two of which occur in the exons and three of which occur in the introns
[12]. One of these nucleotide changes, a translationally silent cytosine to thymine transition at position 6 in
exon 7, causes skipping of exon 7 in the majority of transcripts from SMN2 and give rise to the SMN7 RNA
isoform. The alternative splicing of SMN2 exon 7 is caused by the disruption of an exonic splicing enhancer
(ESE) sequence that is recognized by the SR protein SF2 (splicing factor 2)/ASF (alternative SF) [13] and/or by
the creation of an exonic splicing silencer (ESS) recognized by hnRNP A1 and A2 [14]. Exon 7 is the last coding
exon in SMN1, and the resulting SMN7 protein isoform lacks the C-terminal 16 amino acid residues of the SMN
protein, which are replaced by 4 amino acid residues derived from exon 8 [15]. The SMN7 protein is unable to
self-associate, is degraded more quickly, and is unable to effectively replace the function of the full-length SMN
protein [16-18]. Approximately 20% of SMN2 mRNA transcripts are spliced to include exon 7 and are translated
to the full-length, functional SMN protein; the higher the level of SMN protein, the milder the SMA phenotype
(Figure 1) [19,20].
Figure 1. The genomic structure of the SMN locus.SMN2 SMN1 centromere telomere
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The survival of motor neuron (SMN)1 gene (located at the telomeric end of the chromosome) is transcribed
and spliced normally to generate the SMN mRNA. The SMN mRNA is translated into the SMN protein, which is
assembled into intranuclear Gemini of coiled bodies ('gems'). The effect of the cytosine (C) to thymine (T)
transition (C to uridine [U] in the pre-mRNA) in the SMN2 gene (located at the centromeric end of the
chromosome) on SMN2 exon 7 splicing and SMN protein expression is shown. A minority of the SMN2 pre-
mRNA is spliced to include exon 7 and generate the wild-type SMN mRNA (indicated by the dashed arrow). In
the majority of the SMN2 pre-mRNA exon 7 is spliced out generating the SMN7 mRNA. The SMN7 mRNA is
translated to a shortened form of the SMN protein that is unstable and is unable to self-associate and assemble
into intranuclear gems.
(Adapted with permission from Elsevier Ltd and Khoo B, Akker SA, Chew SL: Putting some spine into
alternative splicing. Trends Biotechnol (2003) 21(8):328-330. © 2003 Elsevier Ltd)
The potential for therapy in SMA is based on correcting the aberrant splicing of the SMN2 gene, and relies on
increasing the inclusion of exon 7 in the SMN2 pre-mRNA. The correction of the aberrant splicing of SMN2 is in
contrast to the treatment of dystrophin-related diseases, in which exon skipping is desired [21]. Progress has
been made in identifying small molecules that increase SMN2 exon 7 inclusion in the mRNA and expression of
the SMN protein, including treatment with various histone deacetylase inhibitors. Examples of these and other
molecules include sodium butyrate [22], phenylbutyrate [23], hydroxyurea [24], sodium valproate [25],
salbutamol [26], plant-derived polyphenols (such as reservatrol and curcumin [27]), and a quinazoline
compound series and an indole compound identified by HTS [28]. The anthracycline aclarubicin is also effective
in increasing SMN2 exon 7 inclusion and SMN protein expression, although the mode of action of this agent is
unclear [29]. Aminoglycoside compounds that promote read-through of premature termination codons also
increase SMN protein expression levels in fibroblasts derived from patients with SMA [15]. The NSAID drug
indoprofen increases levels of SMN protein expressed from the SMN2 gene; this agent does not have an effect
on exon 7 splicing, but may instead act co-translationally to increase expression of the wild-type SMN protein
[30]. Although these small molecules are promising as modulators of exon 7 splicing, they are likely to be
pleiotropic in their effects. To minimize off-target effects, methods that correct the defective splicing of SMN2
exon 7 with improved specificity have been explored. The mechanics of SMN2 exon 7 alternative splicing andthe potential splicing therapies under development in 2007 and 2008 that specifically correct SMN2 exon 7
splicing to compensate for the loss of SMN1 are described.
(sub) Enhancement of exon 7 inclusion by antisense oligonucleotides
Following on from the observation that the ESE in SMN1 exon 7 is disrupted in SMN2 [13], a synthetic SR
protein analog to foster exon 27 inclusion was designed. This comprised a chimeric molecule with a peptide-
nucleic acid (PNA; a peptide-like backbone of nucleobases capable of hybridizing with RNA [31]) covalently
joined to a peptide. The constructed hybrid comprised a PNA antisense oligonucleotide (ASO) moiety, which
targeted nucleotide positions 7 to 18 in SMN2 exon 7, coupled to 10 serine-arginine dipeptide repeats (the
RS10 domain), to form an oligopeptide that can substitute for the natural serine-arginine rich domain of
SF2/ASF. This compound, SMN-RS10, was effective at inducing SMN2 exon 7 inclusion in the mRNA transcript
in vitro [32]. An important observation was that the PNA ASO moiety alone was partially effective in
augmenting the inclusion of exon 7 in SMN2 mRNA, although the effect was strongly enhanced when the RS10
domain was attached to the ASO. The enhancement of exon 7 inclusion in SMN2 mRNA by the addition of the
RS10 domain to the ASO suggests that either SMN-RS10 displaces a repressor protein from an ESS or that the
formation of a secondary structure unfavorable to spliceosomal assembly is inhibited.
To investigate the mechanism of action of SMN-RS10 and optimize the placement of the ASO target (ie, to
identify the SMN1 nucleotide sequence that when targeted by the ASO leads to the most improvement in exon
7 inclusion), a systematic ASO 'walk' along the entire length of SMN2 exon 7 using 2'-O-methoxyethyl (MOE)
ASOs was undertaken [33]. The effects of the MOE ASOs on SMN2 splicing were evaluated with in vitro splicing
assays and verified by transfection of HEK293 cells. MOE ASOs, which have a charged backbone, were
transfected more efficiently than PNA ASOs. Two regions that were inhibitory to exon 7 inclusion in the SMN2
mRNA transcript were identified: one region extends from the nucleotide positions 4 to 22 (region A) and the
other from 34 to 51 (region B), sandwiching a central core region from position 22 to 33 containing a 5' motif
that binds the splicing activator protein transformer 21 (Tra21) [34], as well as another less well-
characterized 3' ESE (Figure 2). Individual MOE ASOs targeting the nucleotide positions 7 to 21 and 34 to 48
were able to increase SMN2 exon 7 inclusion in the mRNA transcript to similar levels observed in the SMN1
mRNA. These MOE ASOs also increased the number of gems in fibroblasts derived from a patient with SMA
suggesting a physiologically significant increase in the amount of functional SMN protein.
Figure 2. Regions in the SMN2 pre-mRNA that inhibit the inclusion of exon 7.
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The exon 7 sequence of the survival of motor neuron (SMN)2 gene is shown in capital letters, with flanking
intronic sequences shown in lower case letters. The position of the cytosine (C) to uracil (U) transition in exon 7
is indicated by the arrow. Inhibitory regions A and B that inhibit the inclusion of exon 7 in the SMN2 mRNA are
shown in pink, and the central core region, which appears to be essential for exon 7 inclusion, is shown in
green. The splicing factors A1 (heterogeneous nuclear ribonucleoprotein A1) [14], SF2/ASF (splicing factor
2/alternative splicing factor) [13], Tra21 (transformer 21) [34], and an unknown splicing activator (?), which
are thought to bind to exon 7, are shown.Androphy and coworkers characterized an inhibitory stem-loop structure that incorporates the 3' end of SMN2
exon 7, including two intronic residues of the 5' splice site [35]. This stem-loop structure was postulated to
sequester the weak 5' splice site of exon 7 and prevent its recognition by the spliceosomal component U1
snRNP. In this regard, it is interesting that ASO 34 to 48 is complementary to the 5' strand of the stem-loop
structure, and may foster exon 7 inclusion by inhibiting the formation of the stem-loop. Similarly, MOE ASO 7
to 21 and the PNA ASO 7 to 18 may encourage the inclusion of exon 7 by inhibiting the binding of splicing
repressor proteins, such as hnRNP A/B proteins; these repressor proteins are thought to bind an ESS motif at
positions 6 to 11 [14], or to spread from other regions when the SF2/ASF ESE motif is absent, such as in SMN2
[36].
Weakening the 3' splice site of exon 8 of the SMN2 gene (e.g., by targeting this site with an ASO) favors exon 7
inclusion, perhaps by a competitive mechanism [37]. Dickson et al increased full-length SMN protein expression
as well as restoration of gems in transfected fibroblasts from patients with SMA with bifunctional 2'-O-methyl
RNA oligonucleotides, which incorporated an antisense moiety that bound to the 3' splice site of exon 8 with an
hnRNP A1-binding motif [38].
Intronic inhibitory elements within the SMN2 pre-mRNA repress the inclusion of exon 7 [39]. Targeting intronic
inhibitory elements instead of exonic elements is an attractive strategy, because this is less likely to interfere
with subsequent steps in mRNA processing, such as mRNA transport or translation. One such element, intronic
splicing silencer element (ISS)-N1, is present within intron 7 of the SMN2 gene and downstream of the 5' splice
site of exon 7. Singh and colleagues demonstrated that binding an ASO to the ISS-N1 element restored SMN2
exon 7 inclusion to the levels observed in SMN1 mRNA [39]. The mapping of the SMN2 ISS-N1 silencer motif
has been refined by conducting a high-resolution ASO walk in intron 7 [40]. This silencer element binds
strongly and specifically to hnRNP A1/A2, and binding of hnRNP A1/A2 appears to underlie the silencing activity
of the ISS-N1 element [40]. The ASOs that were most effective at increasing SMN2 exon 7 inclusion in the
mRNA transcript in HEK293 cells were infused into transgenic mice harboring the human SMN2 gene [40].
These ASOs increased SMN2 exon 7 inclusion in the SMN2 mRNA in transgenic mice, and the most striking
effect was observed in the liver. The inclusion of exon 7 in SMN2 mRNA was increased from a baseline of 21 to
91% over a 4-week ASO-treatment period. Significant increases of 2 to 3-fold in exon 7 inclusion in the SMN2
mRNA were also observed in kidney and muscle. Because these ASOs do not cross the blood-brain barrier, no
increase in exon 7 inclusion was observed in the spinal cord [40].
(sub) Enhancement of exon 7 inclusion by bifunctional tailed ASOs
Bifunctional antisense oligonucleotides were generated by Skordis et al, in which a 5' phosphorothioate RNA tail
containing ESE motifs that bind endogenous SR proteins, or other splicing activator proteins, were combined at
the 3' end of the oligonucleotide with a 2'-O-methyl phosphorothioate ASO moiety targeting positions 2 to 16 of
SMN2 exon 7 [41]. This strategy increased exon 7 inclusion in the SMN2 mRNA from 57% to 84%, both in vitro
and in vivo in fibroblasts isolated from patients with SMA, and partially restored the appearance of gems in the
nuclei of these fibroblasts [41]. Subsequently, similar but unmodified bifunctional RNA ASOs expressed in
recombinant adeno-associated virus (rAAV) vectors increased exon 7 inclusion in the SMN2 mRNA, partially
restored the appearance of gems and increased SMN protein levels [42]. In 2004, Schümperli and Pillai utilized
the same bifunctional oligonucleotide design plus an additional feature wherein the oligonucleotides were
coupled to a modified U7 small nuclear RNA (U7 Sm OPT, reviewed in reference [43]) at the 3' end to target
the bifunctional oligonucleotide to the spliceosome and increase its efficacy in modifying splicing. Interestingly,
targeting the ASO moiety to position 2 to 19 of the SMN2 pre-mRNA (ASO 02-19–U7 Sm OPT, approximately
corresponding to inhibitory region A) was only partially effective and induced exon 7 inclusion in SMN2 mRNA
only to a maximum of 41% from a baseline value of 10%. Furthermore, by removing the ESE tail, ASO 02-19–U7 Sm OPT had the reverse effect and induced exon 7 skipping in both SMN1 and SMN2 pre-mRNA. The
increased exon skipping was attributed to steric hindrance of the 3' splice site in both SMN1 and SMN2 by the
U7 Sm OPT stem-loop. Targeting positions 31 to 48 (ASO 31-48–U7 Sm OPT, approximately corresponding to
inhibitory region B) was more successful, with the ESE-ASO 31-48–U7 Sm OPT construct able to boost exon 7
inclusion in SMN2 mRNA to 89% [44].
A series of experiments evaluated the ability of various ESE sequences within the 5' phosphorothioate RNA tail
to increase exon 7 inclusion in the SMN2 mRNA. The first series of experiments by Skordis et al utilized a
purine-rich ESE sequence (GGAGGAC) to recruit SF2/ASF [41]. A bifunctional ASO incorporating a tail with a
different ESE sequence (TGCGTC) optimized for the binding of the SRp55 SR protein, achieved only partial
efficacy, with an increase to 42% of exon 7 inclusion [45]. When a second ESE sequence optimized for SF2/ASF
binding (CACACGA) was used, the construct had the reverse effect and caused exon 7 skipping. Similarly, ESE
tails optimized for binding of the splicing enhancer proteins SRp40, SC35 and TIA-1 caused exon 7 skipping in
this context [45]. This firstly demonstrates that not all splicing enhancer proteins are effective in causing exon
7 inclusion and some might even be counterproductive in causing skipping. Secondly, it is likely that the
original purine-rich ESE sequence (GGAGGAC) did not recruit SF2/ASF, but actually recruited Tra21, a splicing
activator protein, which naturally binds to a similar purine-rich ESE in the middle of exon 7 (Figure 2) [34].
Infection of immortalized fibroblasts from a patient with SMA with bifunctional U7 cassettes coupled to lentiviral
vectors, increased SMN2 mRNA exon 7 inclusion from 54% at baseline to 75% using the ESE-ASO 02-19–U7
Sm OPT and to 97% using the ESE-ASO 31-48–U7 Sm OPT [44]. SMN protein levels were increased from the
control levels of approximately 17% to approximately 50% for both constructs, and intranuclear gem numbers
were also significantly increased from 17 gems/100 nuclei to 49 gems/100 nuclei [44].
(sub) Trans-splicing as a means of replacing exon 7
Lorson and colleagues developed a trans-splicing strategy to replace exon 7 in SMN2 mRNA. This approach
relied on the expression of a therapeutic trans-splicing RNA (tsRNA – reviewed by Garcia-Blanco [46]), which
was engineered to base-pair to intron 6 of SMN2 [47]. The tsRNA also contained an optimized BPS and a 3'
splice site, the SMN1 exon 7 sequence and a hemagglutinin tag to allow for easy monitoring of trans-splicing.
Splicing occurred in trans between the SMN2 pre-mRNA and the tsRNA, such that the SMN1 exon 7 sequence
was spliced into the SMN2 mRNA. In their proof-of-principle study, trans-splicing was demonstrated between
the tsRNA and the native SMN2 pre-mRNA in HeLa cells. Furthermore, by placing the tsRNA within an rAAV
vector and infecting fibroblasts from patients with SMA, trans-splicing was observed between the native SMN2
pre-mRNA and the tsRNA, and intranuclear gems and snRNP assembly in nuclear extracts from these cells
(measured using an in vitro assay) were restored [47].
Re-engineering APOB mRNA to lower cholesterol
APOB is the principal structural apolipoprotein in LDL, very (V)LDL, intermediate-density lipoprotein (IDL),
lipoprotein(a) (Lp(a)) and chylomicron particles [48]. The APOB pre-mRNA is composed of 29 exons, all of
which are constitutively spliced into the mature APOB mRNA. There are two natural protein isoforms, the full-
length APOB100 and the C-terminal truncated APOB48 forms. APOB100 is synthesized in the liver and is
required for the assembly of VLDL, IDL, LDL and Lp(a) particles. Along with APOE, APOB100 is the ligand for
the LDL receptor. Excess levels of the APOB100-containing particles LDL and Lp(a) have been implicated in
atherogenesis [49]. The APOB48 isoform is synthesized in the intestine, is identical to the N-terminal 48% of
the APOB100 protein, and is required for chylomicron assembly and intestinal fat transport. These chylomicrons
are cleared from the circulation by interaction of APOE with the chylomicron remnant receptor; APOB48 cannot
bind to the LDL receptor as it lacks the C-terminal domain necessary for binding. The APOB48 isoform isgenerated by tissue-specific RNA editing of the CAA codon to a premature UAA termination codon in the
intestine. The APOB48 mRNA is edited by a protein complex known as the editosome, which consists of the
catalytic subunit APOBEC-1 (APOB mRNA-editing enzyme, catalytic polypeptide-1) and accessory factors. The
RNA editing site and mooring sequence necessary for editosome binding and function are within exon 26 of the
APOB mRNA [50]. Because of the central role of APOB100 in atherosclerosis, this isoform has become a major
therapeutic target. Down-regulation of APOB100 expression is expected to decrease total cholesterol, LDL and
Lp(a) levels, and therefore prevent the development of atherosclerosis.
Modifying APOB splicing was hypothesized to cause the expression of an alternative isoform of APOB. Exon 27
was selected as the target for three reasons. First, translation of the APOB mRNA lacking exon 27 (skip 27
mRNA) would generate a C-terminally truncated isoform of APOB100, APOB87SKIP27, which is similar to the C-
terminal truncations observed in some patients with mutations in APOB causing hypobetalipoproteinemia [51].
Heterozygotes for these mutant alleles of APOB have low cholesterol and LDL levels, have lowered risks of heart
attacks, and live significantly longer than normal, although these individuals may be susceptible to fat
accumulation in the liver [52]. Second, the 5' splice site of exon 27, when scored for its similarity to the splice-
site consensus sequence using the Shapiro and Senapathy position weight matrix, was the weakest of all the 5'
splice sites of the internal exons of APOB [53]. As constitutive 5' splice sites in general demonstrate better
scores than the alternatively spliced 5' splice sites [54], APOB exon 27 would be the most amenable to
alternative splicing. Third, as the sequences necessary for RNA editing are present in exon 26, the skip 27
mRNA should be edited as usual in the intestine and APOB48 expression should be unaffected (Figure 3).
Figure 3. Skipping APOB exon 27 causes the expression of APOB87SKIP27,a C-
terminally truncated isoform of APOB.
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Constitutive exon 27 inclusion. Two isoforms of apolipoprotein B (APOB), APOB48 and APOB100, which
both include exon 27 can be generated from the APOB mRNA. The APOB100 isoform is synthesized in the liver
and is assembled into LDL particles, which transport cholesterol from the liver to the rest of the body and which
have been implicated in atherosclerosis. APOB48 is identical to the N-terminal 48% of APOB100 and is
synthesized in the intestine by tissue-specific RNA editing within exon 26, which generates a prematuretermination codon (PTC; indicated by the red box – sequence changed from CAA to UAA, where A = adenine, C
= cytosine and U = uracil) and the C-terminally truncated protein. The APOB48 isoform is assembled into
chylomicrons that transport dietary fat from the intestine. Induced exon 27 skipping. Modifying APOB
splicing by the skipping of exon 27 can lead to the expression of two alternative isoforms of APOB, APOB87SKIP27
and APOB48. Because skipping exon 27 induces a frameshift, a PTC is generated within exon 28 (indicated by
the red box). The skip 27 mRNA is translated in the liver to the APOB87SKIP27 isoform, which contains the N-
terminal 87% of APOB100 plus a 37 amino acid divergent sequence derived from the frameshifted sequence of
exon 28. However, as RNA editing in the intestine generates the PTC within exon 26, intestinal APOB48
expression is unaffected.
Therefore 2'-O-methyl ASOs targeting the splice sites flanking APOB exon 27 and to the BPS of intron 26-27
were designed and transfected into HepG2 cells, which naturally express APOB100 [55]. Combination ASOs
targeting two elements simultaneously in a single ASO induced exon 27 skipping, and this was most effective
when both the 3' splice site and BPS were targeted. In contrast, targeting predicted ESE motifs within exon 27
to interfere with SR protein binding did not have a significant effect on exon skipping, suggesting that the
constitutive incorporation of exon 27 is more dependent on the splice sites than on exonic elements, or that a
there is functional redundancy between the exonic elements [55].
Chabot and colleagues successfully utilized A1-tailed bifunctional oligonucleotides to induce alternative splicing
in the Bcl-x pre-mRNA [56]. A bifunctional oligonucleotide consisting of a combination ASO targeting two splice
sites plus an RNA tail was designed to bind the hnRNP A1 protein to encourage skipping of exon 27; however,
this A1 tail did not augment exon-skipping in APOB pre-mRNA, but paradoxically partially reversed the skipping
of exon 27 [55]. Therefore, the splice site and BPS ASOs may not function through a simple interference with
splicing-factor binding. Instead, hybridization of the combination ASOs is likely to induce a secondary structure
that is unfavorable to exon 27 inclusion. It is possible that recruitment of hnRNP A1 is counterproductive, as
this may cause unwinding of the secondary structure [55].
Lastly, we demonstrated that combination ASO-transfected HepG2 cells were able to translate the skip 27
mRNA to a shortened isoform of APOB100, APOB87SKIP27, which included the N-terminal 87% (3929 amino
acids) of APOB100, along with a divergent 37 amino acid peptide at the C-terminus and ending in a premature
termination codon within the exon 28 sequence [55]. Therefore, the induction of APOB87SKIP27 expression in
vivo should lead to decreased LDL and cholesterol levels, such as occurs in patients with
hypobetalipoproteinemia.
As mentioned previously, because intestinal APOB mRNA editing and APOB48 expression rely on sequences
within exon 26, exon 27 skipping should not affect APOB48 expression. This is in contrast to methods that rely
on a generalized downregulation of APOB mRNA levels, such as chimeric ASO-mediated RNase H degradation
[57], and RNA i [58]. These latter methods have been demonstrated to reduce APOB100 levels and therefore
circulating levels of cholesterol and LDL, but they also reduce the levels of APOB48 and circulating levels of
chylomicrons, an unwanted side effect expected to interfere with the transport of fat from the intestine.
Conclusion
The potential treatment of SMA and high cholesterol by splicing therapeutics exemplify two key uses of this
strategy: first, correcting defective splicing caused by gene mutations, such as the replacement of the defective
SMN1 gene in SMA with SMN2; second, to re-engineer normal pre-mRNAs to achieve the desired physiological
effects, such as the re-engineering of APOB pre-mRNA to reduce cholesterol levels.In 2008, the development of various therapeutic strategies to correct SMN2 splicing has been particularly
active. The challenge now is to identify reliable and safe methods of applying these therapeutic concepts to the
bedside. ASOs are known to accumulate in the liver when administered in vivo [59], and have been shown to
switch splicing in this organ when administered to mice intraperitoneally and orally [60]. In addition, ASOs
targeted against the ISS-N1 element and infused into mice are able to increase exon 7 inclusion in SMN2 mRNA
in the liver, kidney, and to a lesser extent, in muscle [40]. With regards to splicing therapeutics directed
against APOB, as the liver is the principal target organ, ASOs are natural candidates for such an application.
The next stage in the development of these APOB ASOs will be to demonstrate their effectiveness in lowering
LDL cholesterol in vivo, and then to demonstrate that the APOB ASOs reduce the risk of clinically relevant
endpoints.
With regards to SMN2, however, there are obstacles remaining in the delivery of ASO-based therapies,
particularly because the blood-brain barrier protects the CNS from these agents [61]. SMN2 ASOs administered
into the systemic circulation are not able to modify the splicing of SMN2 in the spinal cord because the ASOs
cannot cross the blood-brain barrier [40]. The blood-brain barrier can be bypassed by administering ASOs to
the CSF, either intrathecally or intracerebroventricularly; this strategy has been shown to be effective in
downregulating superoxide dismutase in spinal motor neurons and slowing disease progression in a mouse
model of amyotrophic lateral sclerosis [62]. Lentiviral- or rAAV-based vectors represent an alternative
technology that could allow splicing-based therapies to be administered efficiently to the CNS. The rAAV-based
vectors can be used to transduce spinal cord neurons by retrograde transport [63]. However, other concerns
exist with regard to the use of viral vectors in the CNS, particularly related to the induction of an immune
response in patients previously exposed to AAV [64]. Therefore, both delivery strategies for splicing therapy
(viral and nonviral), will be worth pursuing.
Lastly, it is not yet known if the modification of SMN2 splicing and restoration of the expression of the SMN
protein can reverse the pathophysiology of SMA and the death and degeneration of spinal motor neurons to
achieve clinically relevant outcomes. This is analogous to the situation with Duchenne muscular dystrophy
(DMD). The intramuscular injection of ASOs has been demonstrated to successfully restore local dystrophin
expression in patients with DMD. However, in a short follow-up study of 28 days, restoration of local dystrophin
expression was not accompanied by an increase in muscular strength [65]. Thus, the practical application of
splicing therapeutics with regard to SMN2 is at least some distance away and awaits further development in
vivo.
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